Treatment of Stage I Breast Cancer: The NSABP Experience

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The results of two clinical trials carried out by the National Surgical Adjuvant Breast and Bowel Project are presented. A total of 559 histologically node-negative patients were randomised and assigned treatment in the two protocols. In the oestrogen receptor-negative patients with breast cancer, treatment with methotrexate and 5-fluorouracil produced a 31% reduction in treatment failure at 4 years when compared to no systemic treatment. In the oestrogen receptor-positive patients, treatment with tamoxifen produced a 26% reduction in treatment failure at 4 years in comparison to placebo treatment. In both protocols, this benefit was observed both in patients aged under and over 50 years.

Related collections

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (doi): 10.1159/issn.0018-5051

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISBN: 978-3-8055-5105-2

ISBN: 978-3-318-01977-3

ISSN (Print): 0018-5051

ISSN (Electronic): 2571-6603

Publication date Subscription-year: 1989

Publication date (Print): 1989

Publication date (Electronic): 02 December 2008

Volume: 32

Issue: Suppl 1

Pages: 175-180

Affiliations

National Surgical Adjuvant Project for Breast and Bowel Cancers (NSABP), University of Pittsburgh, Pa. USA

Article

Publisher ID: 181340 Other ID: Horm Res 1989;32:175–180

DOI: 10.1159/000181340

SO-VID: 91642dfa-e67d-44d9-8b15-cf24460df86e

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Treatment of Stage I Breast Cancer: The NSABP Experience

Read this article at

Abstract

Related collections

Karger: Endocrinology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 423